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In animal studies, the specificity of L-NMMA can be more accurately assessed. Inhibition of NOS activity with L-NMMA lead in a dose-dependent manner to an increased glomerular capillary permeability of albumin (6) , and an eNOS knock-out model developed significantly increased albuminuria (7) . These experiments substantiate the claim that L-NMMA profoundly inhibits eNOS and as consequence causes albuminuria.
Tsikas et al. suggest that other mediators, in particular thromboxane, may be involved. Because of the strong evidence (3,4,7) we are convinced that the changes observed are predominantly or even exclusively caused by specific NOS inhibition, but we cannot rule out that other factors might have contributed to albuminuria. In principle, thromboxane could be one of these mediators, but several previous studies suggest that this may not be the case. In the cited publication of Francois et al. (8), chronic L-NAME administration elevates concentrations of thromboxane B 2 (TxB 2 ) and 8-isoprostanes. However, urinary albumin excretion did not change over time. In streptozotocin-induced diabetic rats the thromboxane synthetase inhibition resulted in a significant reduced urinary TxB 2 excretion, whereas urinary protein excretion did not differ significantly (9) .
Thus our study demonstrates that reduced NO activity causes an increase in albuminuria in humans.
